Republic Act No. 6675: Reporter: Manamparan Hosny M

REPUBLIC ACT No.
6675
Reporter:
Manamparan Hosny M.
“AN ACT TO PROMOTE, REQUIRE AND
ENSURE THE PRODUCTION OF AN
ADEQUATE SUPPLY, DISTRIBUTION, USE AND
ACCEPTANCE OF DRUGS AND MEDICINES
IDENTIFIED BY THEIR GENERIC NAMES”
September 13, 1988
Section 2 - Statement of Policy
▷ To promote, encourage and require the use of generic terminology in the importation,
manufacture, distribution, marketing, advertising and promotion, prescription and
dispensing of drugs;
▷ To ensure the adequate supply of drugs with generic names at the lowest possible cost
and endeavor to make them available for free to indigent patients;
▷ To encourage the extensive use of drugs with generic names through a rational system
of procurement and distribution;
▷ To emphasize the scientific basis for the use of drugs, in order that health professionals
may become more aware and cognizant of their therapeutic effectiveness; and
▷ To promote drug safety by minimizing duplication in medications and/or use of drugs

with potentially adverse drug interactions.
Section 4- The Use of Generic Terminology for Essential
Drugs and Promotional Incentives.
(a) In the promotion of the generic names for pharmaceutical products, special
consideration shall be given to drugs and medicines which are included in the
Essential Drugs List to be prepared within one hundred eighty (180) days from
approval of this Act and updated quarterly by the Department of Health on the
basis of health conditions obtaining in the Philippines as well as on
internationally accepted criteria.
(b) The exclusive use of generic terminology in the manufacture, marketing and
sales of drugs and medicines, particularly those in the Essential Drugs List,
shall be promoted through such a system of incentives as the Board of
Investments jointly with the Department of Health and other government
agencies as may be authorized by law, shall promulgate in accordance with
existing laws, within one hundred eighty (180) days after approval of this Act.
Section 5 - Posting and Publication
▷ The Department of Health shall publish
annually in at least two (2) newspapers of
general circulation in the Philippines the
generic names, and the corresponding
brand names under which they are
marketed, of all drugs and medicines
available in the Philippines.
Section 6 - Who Shall Use Generic Terminology
▷ (a) All government health agencies and their personnel as
well as other government agencies shall use generic
terminology or generic names in all transactions related to
purchasing, prescribing, dispensing and administering of
drugs and medicines.
▷ (b) All medical, dental and veterinary practitioners,

including private practitioners, shall write prescriptions
using the generic name. The brand name may be included
if so desired.
Section 6 - Who Shall Use Generic Terminology
▷ (c) Any organization or company involved in the manufacture,
importation, repacking, marketing and/or distribution of drugs
and medicines shall indicate prominently the generic name of the
product. In the case of brand name products, the generic name
shall appear prominently and immediately above the brand name
in all product labels as well as in advertising and other
promotional materials.
▷ (d) Drug outlets, including drugstores, hospital and non-hospital

pharmacies and non-traditional outlets such as supermarkets and
stores, shall inform any buyer about any and all other drug
products having the same generic name, together with their
corresponding prices so that the buyer may adequately exercise,
his option.
Section 7 - Provision on Quality, Manufacturer’s
Identity and Responsibility
▷ In order to assure responsibility for drug

quality in all instances, the label of all drugs
and medicines shall have the following:
name and country of manufacture, dates of
manufacture and expiration. The quality of
such generically labeled drugs and
medicines shall be duly certified by the
Department of Health.
Section 8 - Required Production
▷ Subject to the rules and regulations
promulgated by the Secretary of Health,
every drug manufacturing company
operating in the Philippines shall be
required to produce, distribute and make
available to the general public the medicine
it produces, in the form of generic drugs.
Section 9 - Rules and Regulations
▷ The implementation of the provisions of this Act
shall be in accordance with the rules and regulations
to be promulgated by the Department of Health.
Rules and regulations with penal sanctions shall be
promulgated within one hundred eighty (180) days
after approval of this Act and shall take effect
fifteen (15) days after publication in the Official
Gazette or in two (2) newspapers of general
circulation.
Section 10 - Authority to Import
▷ Within three (3) years from the effectivity of this Act, extendible
by the President for another two (2) years and during periods of
critical shortage and absolute necessity, the Department of
Health is hereby authorized to import raw materials of which
there is a shortage for the use of Filipino-owned or controlled
drug establishments to be marketed and sold exclusively under
generic nomenclature. The President may authorize the
importation of raw materials tax and duty-free. The Secretary of
Health shall ensure that the imported raw materials are allocated
fairly and efficiently among Filipino-owned or controlled drug
establishments. He shall submit to the Office of the President and
to Congress a quarterly report on the quantity, kind and value of
the raw materials imported.
Section 11- Education drive
▷ The Department of Health jointly with the Department of
Education, Culture and Sports, Philippine Information Agency and
the Department of Local Government shall conduct a continuous
information campaign for the public and a continuing education
and training for the medical and allied medical professions on
drugs with generic names as an alternative of equal efficacy to
the more expensive brand name drugs.
Section 12 - Penalty
▷ (a) for the first conviction, he shall suffer the penalty of reprimand
which shall be officially recorded in the appropriate books of the
Professional Regulation Commission.
▷ (b) for the second conviction, the penalty of fine in the amount of
not less than two thousand pesos (P2,000.00) but not exceeding
five thousand pesos (5,000.00) at the discretion of the court.
Section 12 - Penalty
(c) for the third conviction, the penalty of fine in the amount of not
less than five thousand pesos (P5,000.00) but not exceeding then
thousand pesos (P10,000.00) and suspension of his license to
practice his profession for thirty (30) days at the discretion of the
court.
(d) for the fourth and subsequent convictions, the penalty of fine of
not less than ten thousand pesos (P10,000.00) and suspension of his
license to practice his profession for one year or longer at the
discretion of the court.
Section 14 - Repealing Clause
▷ The provisions of any law, executive order,
presidential decree or other issuances
inconsistent with this Act are hereby
repealed or modified accordingly.
Section 15 - Effectivity
▷ This Act shall take effect fifteen (15) days
after its complete publication in the Official
Gazette or two (2) newspapers of general
circulation.
Thanks!
Any questions?

Republic Act No. 6675: Reporter: Manamparan Hosny M

Uploaded by

Copyright:

Available Formats

Republic Act No. 6675: Reporter: Manamparan Hosny M

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Republic Act No. 6675: Reporter: Manamparan Hosny M

Uploaded by

Copyright:

Available Formats

REPUBLIC ACT No.

▷ To promote drug safety by minimizing duplication in medications and/or use of drugs

▷ (b) All medical, dental and veterinary practitioners,

▷ (d) Drug outlets, including drugstores, hospital and non-hospital

▷ In order to assure responsibility for drug

You might also like